-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 23, Cinda Biotech and Reindeer Medical jointly announced that the fully human BCMA chimeric antigen receptor autologous T cell injection developed by both parties (Cinda Biologics R&D code: IBI326; Reindeer Medical R&D code: CT103A) passed During the publicity period of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), the "breakthrough treatment drug variety" was included, and the proposed indication is relapsed/refractory multiple myeloma (R/R MM).
Multiple myeloma is one of the most common blood cancers and a malignant disease in which clonal plasma cells proliferate abnormally.
At the 61st American Annual Meeting of Hematology (ASH) held in 2019, Caribou Medical and Innovent Biosciences together orally reported the data of a clinical study of IBI326 in the treatment of relapsed/refractory multiple myeloma.
In January 2021, the latest clinical research results of this innovative drug have been recognized by international authorities again-a team of Reindeer Medical and Professor Zhou Jianfeng from the Department of Hematology, Tongji Hospital of Huazhong University of Science and Technology The latest research results on the efficacy and safety of multiple myeloma were published in Blood, a well-known academic journal of hematology.
Dr.
Ms.
IBI326 is a CAR-T cell therapy for B cell maturation antigen (BCMA) jointly developed by Innovent and Reindeer Medical Pharmaceuticals.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Reference materials:
[1] The BCMA CAR-T jointly developed by Cinda Biotech and Reindeer Medical has been recognized as a breakthrough therapeutic drug by the National Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma.